Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· February 19, 2026

Oceaneering projects $390M–$440M EBITDA for 2026 as ADTech drives multiyear growth

View original at seekingalpha.com
Oceaneering projects $390M–$440M EBITDA for 2026 as ADTech drives multiyear growth Earnings Call Insights: Oceaneering International, Inc…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Achieved 7% improvement in ROV pricing

    80% confidence
  • Interest in autonomous forklifts is high with adoption depending on customer readiness

    80% confidence
  • Not pursuing big industry consolidation M&A but sees potential for bolt-on technology acquisitions

    80% confidence
  • Oceaneering closed out 2025 with strong execution across the business, making continued progress against strategic priorities

    80% confidence
  • Government services lead times for ADTech projects vary quite a bit, with some ramping quickly and others requiring longer engineering and prototyping phases

    80% confidence
  • Organic capital expenditures for 2026 forecasted between $105 million and $115 million, with 40% allocated to growth and 60% to maintenance

    80% confidence
  • Cash balance increased to $689 million at year-end, further strengthening financial flexibility

    80% confidence
  • Achieved 140 basis points EBITDA margin expansion in 2025

    80% confidence
  • Net income of $178 million or $1.76 per share represents a 217% increase year-over-year, largely due to $156 million discrete tax benefit related to release of U.S. valuation allowances

    80% confidence
  • ROV uptime was 99% for the second consecutive year

    80% confidence
  • 2025 order intake was $3.7 billion with a book-to-bill ratio of 1.33

    80% confidence
  • Oceaneering's offshore, maritime, and space expertise translates across defense and energy with unique SUBSAFE certifications and capabilities in submarine sustainment and space systems

    80% confidence
  • Free cash flow for 2026 anticipated to be $100 million to $120 million, with year-over-year reduction primarily reflecting early receipt of $37 million in customer payments in Q4 2025

    80% confidence
  • IMDS integrates machine vision, machine learning, and AI for enhanced inspection capabilities that can be deployed subsea with ROVs

    80% confidence
  • 2026 EBITDA projected between $390 million and $440 million with year-over-year improvements in all segments except OPG

    80% confidence
  • Consolidated revenue in 2026 projected to grow in the low to mid-single-digit percentage range, with ADTech revenue improving significantly year-over-year

    80% confidence
  • Balance sheet strength and cash growth gives more flexibility and opportunity to do more when the time is right

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com